Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 15:11:15.
doi: 10.25259/JCIS_6_2020. eCollection 2021.

Useful Parameters in Dynamic Contrast-enhanced Ultrasonography for Identifying Early Response to Chemotherapy in a Rat Liver Tumor Model

Affiliations

Useful Parameters in Dynamic Contrast-enhanced Ultrasonography for Identifying Early Response to Chemotherapy in a Rat Liver Tumor Model

Ryosuke Taiji et al. J Clin Imaging Sci. .

Abstract

Objectives: The objective of the study is to determine a parameter on the time-intensity curve (TIC) of dynamic contrast-enhanced ultrasonography (DCE-US) that best correlates with tumor growth and to evaluate whether the parameter could correlate with the early response to irinotecan in a rat liver tumor model.

Material and methods: Twenty rats with tumors were evaluated (control: Saline, n = 6; treatment: Irinotecan, n = 14) regarding four parameters from TIC: Peak intensity (PI), k value, slope (PI × k), and time to peak (TTP). Relative changes in maximum tumor diameter between day 0 and 10, and parameters in the first 3 days were evaluated. The Mann-Whitney U-test was used to compare differences in tumor size and other parameters. Pearson's correlation coefficients (r) between tumor size and parameters in the control group were calculated. In the treatment group, relative changes of parameters in the first 3 days were compared between responder and non-responder (<20% and ≥20% increase in size on day 10, respectively).

Results: PI, k value, PI × k, and TTP significantly correlated with tumor growth (r = 0.513, 0.911, 0.665, and 0.741, respectively). The mean RC in k value among responders (n = 6) was significantly lower than non-responders (n = 8) (mean k value, 4.96 vs. 72.5; P = 0.003).

Conclusion: Parameters of DCE-US could be a useful parameter for identifying early response to irinotecan.

Keywords: Biomarkers; Colon cancer; Contrast media; Irinotecan; Rats; Ultrasonography.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1:
Figure 1:
Experimental protocol. Maximum tumor diameter was measured on days 0, 3, and 10, and DCE-US was performed on days 0 and 3. Saline was injected in the first step (n = 6) and irinotecan in the second step (n=14). DCE-US: Dynamic contrast-enhanced ultrasonography.
Figure 2:
Figure 2:
DCE-US and the fitted curve constructed from the raw data. DCE-US was conducted for 85 s and the following four parameters were extracted from the fitted curve: PI, k value, wash-in slope (PI × k), and TTP. DCE-U: Dynamic contrast-enhanced ultrasonography, PI: Peak intensity, TTP: Time to peak.
Figure 3:
Figure 3:
Representative responder and non-responder fitted curves. Time-intensity curves on days 0 and 3 and fitted curves after modelization at baseline for a responder (a, b, and e, respectively) and a non-responder (c, d, and f, respectively). In the responder, TTP shortened 1.2 s and PI decreased 1.2 dB. In the non-responder, TTP shortened 5.2 s and PI increased 3.9 dB. The relative change of TTP in the non-responder was shorter than in the responder. TTP: Time to peak, PI: Peak intensity.
Figure 4:
Figure 4:
Relative change in the four DCE-US parameters between days 0 and 3 (second step). The k value was significantly lower in the responder group (4.96%) than in the non-responder group (72.5%, P=0.003). Significant difference was also found for TTP between the responders (2.45%) and non-responders (−27.4%) groups (p = 0.044). DCE-US: Dynamic contrast-enhanced ultrasonography, TTP: Time to peak, PI: Peak intensity.

Similar articles

Cited by

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, et al. NCCN guidelines insights: Colon cancer, Version 2.2018. J Natl Compr Cancer Netw. 2018;16:359–69. doi: 10.6004/jnccn.2018.0021. - DOI - PMC - PubMed
    1. van Cutsem E, Cervantes A, Adam R, Sobrero A, van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386–422. doi: 10.1093/annonc/mdw235. - DOI - PubMed
    1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45:228–47. doi: 10.1016/j.ejca.2008.10.026. - DOI - PubMed
    1. Baccala A, Jr, Hedgepeth R, Kaouk J, Magi-Galluzzi C, Gilligan T, Fergany A. Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib. Int J Urol. 2007;14:1095–7. doi: 10.1111/j.1442-2042.2007.01902.x. discussion 1097. - DOI - PubMed